Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;40(2):126-130.
doi: 10.15537/smj.2019.2.23913.

Gastrointestinal stromal tumors. A clinicopathological study

Hanan M Alghamdi  1 , Samir S Amr, Mohamed A Shawarby, Salwa S Sheikh, Ahmed A Alsayyah, Ali M Alamri, Mona H Ismail, Ahmed Almarhabi, Munir A Alrefaee, Muhammad I Ahmed
Affiliations

Gastrointestinal stromal tumors. A clinicopathological study

Hanan M Alghamdi et al. Saudi Med J. 2019 Feb.

Abstract

Objectives: To evaluate the clinical presentations and immunohistochemical (IHC) properties of gastrointestinal stromal tumors (GISTs) and to compare them to internationally published data.

Methods: Thirty-six patients diagnosed with GISTs between January 1997 and December 2015 were retrospectively studied in 2 tertiary hospitals. Immunohistochemical staining was carried out prospectively when it has not been completed fully at the beginning. Results: The median age of patients was 54 years (range; 17-81 years). Predominantly, we found more females were affected. The male to female ratio was 1:1.7. The most frequently affected organs were the stomach (63.8%) followed by small bowel (25%) and colorectal region (8.4%). Abdominal pain was the most frequent presentation in 33.3% of the patients then gastrointestinal (GI) bleeding in 30.5%. Most of the gastric GISTs were at early stages at presentation: stage 1 and II (60.8%), while in non-gastric GISTs, the tumor stage was advanced: stage III and IV (69.3%). The IHC characteristic of GIST in descending order showed positivity for vimentin (88.9%), CD117 (83.3%), CD34 (77.8%), Ki67 (63.9%), SMA (38.9%), desmin (27.8%), and S100 (19.4%).

Conclusion: Gastrointestinal stromal tumors in our study demonstrates a major similar feature as the published international data. However, minor differences do exist in terms of clinical features and immunohistochemistry.

PubMed Disclaimer

References

    1. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007;369:1731–1741. - PubMed
    1. Zhang W. Molecular approaches to resolve diagnostic dilemmas:the case of gastrointestinal stromal tumor and leiomyosarcoma. Future Oncol. 2007;3:629–637. - PubMed
    1. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. Activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–710. - PubMed
    1. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors:A consensus approach. Hum Pathol. 2002;33:459–465. - PubMed
    1. Von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, et al. Gastrointestinal stromal tumors, version 2.2014:Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014;12:853–862. - PubMed

MeSH terms